Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Apr 24, 2023 (3 years ago)

Gabapentin Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Product mixup: one foreign tablet found in product.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Gabapentin Tablets, USP 600 mg, packaged in Cartons of 100 tablets (10 tablets per blister pack x 10), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. East Windsor, NJ 08520 Distributed by: Major Pharmaceuticals 17177 N Laurel Park Dr., Suite 233 Livonia, MI 48152 USA, NDC 0904-6823-61

Affected NDC 0904-6823-61

Compare with the code on your package — it is the most precise check available.

Drug: Gabapentin Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Gabapentin
NDC 00904-6823
600 mg/1 Tablet, Film Coated
Oral
Major Pharmaceuticals Rx
Recalling firm
The Harvard Drug Group
NDC code
0904-6823-61
Origin
TN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0570-2023 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Gabapentin recalls

See all
Class II · Moderate risk

Gabapentin Capsules

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Ongoing Impurity / degradation The Harvard Drug Group LLC NDC 0904-6665-61 D-0031-2026
Class II · Moderate risk

Gabapentin Capsules

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Ongoing Impurity / degradation The Harvard Drug Group LLC NDC 0904-6665-61 D-0030-2026
Class II · Moderate risk

Gabapentin Capsules

Defective container; blister packaging inadequately sealed.

Ongoing Packaging defect The Harvard Drug Group LLC NDC 55154-3363-0 D-0508-2025
Class II · Moderate risk

Gabapentin Capsules

Defective container; blister packaging inadequately sealed.

Ongoing Packaging defect The Harvard Drug Group LLC NDC 0904-6665-61 D-0507-2025

Other recalls by The Harvard Drug Group

All 2023 recalls
Class II · Moderate risk

Omega-3-Acid

Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.

Ongoing Failed specification The Harvard Drug Group LLC D-0493-2026